What question did this study set out to answer?

To investigate whether canakinumab reduces major cardiovascular event rates and preserves renal function in post-myocardial infarction patients with chronic kidney disease.

August 25, 2026Journal of the American College of CardiologyOpen Access

Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease

Q: What are the key findings of this study?

Among 10,061 post-myocardial infarction patients (1,875 with CKD), canakinumab reduced major adverse cardiovascular event rates without adverse clinical renal events.

Q: What is the clinical evidence from this study?

Study design: RCT. Population: Chronic Kidney Disease (n=10061). Intervention: Canakinumab vs. Placebo. Primary outcome: Incident myocardial infarction, stroke, hospitalization for unstable angina requiring urgent revascularization, cardiovascular death, or death from any cause.

View Full Paper

Ask AI

Bookmark

Key result

Canakinumab reduces MACE in post-MI patients without adverse clinical renal events.

n=10,061

Why the study?

Does canakinumab reduce cardiovascular events in stable post-myocardial infarction patients with elevated hsCRP and chronic kidney disease?

Key Points

To investigate whether canakinumab reduces major cardiovascular event rates and preserves renal function in post-myocardial infarction patients with chronic kidney disease.
Randomized, double-blind trial allocating post-myocardial infarction patients with high-sensitivity C-reactive protein ≥2 mg/l to subcutaneous placebo or canakinumab (50, 150, or 300 mg every 3 months; NCT01327846).
Followed 10,061 participants (including 1,875 with baseline eGFR <60 ml/min/1.73 m²) over a median of 3.7 years (maximum 5 years).
Tracked incident myocardial infarction, stroke, hospitalization for unstable angina, cardiovascular death, and all-cause mortality alongside serial assessments of eGFR, creatinine, and urine albumin-to-creatinine ratio.
Canakinumab significantly reduced major adverse cardiovascular event rates in high-risk atherosclerosis patients with chronic kidney disease.
Cardiovascular risk reduction was especially pronounced in patients demonstrating a robust anti-inflammatory response following initial therapy.
Cardiovascular risk benefits occurred without an increase in adverse clinical renal events or deleterious changes in renal function.

Study Design

Type

RCT (n=10,061)

Randomization

randomly allocated

Structured PICO

Does canakinumab reduce cardiovascular events in stable post-myocardial infarction patients with elevated hsCRP and chronic kidney disease?

Population

10,061 stable post-myocardial infarction patients with hsCRP ≥ 2mg/l, including 1,875 with baseline eGFR <60 ml/min/1.73 m2, followed for a median of 3.7 years.

Intervention

Canakinumab (50, 150, or 300 mg) given subcutaneously once every 3 months

Comparator

Placebo

Outcome

Composite of incident myocardial infarction, stroke, hospitalization for unstable angina requiring urgent revascularization, cardiovascular death, or death from any causecomposite

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Inhibition of IL-1β with canakinumab reduces major adverse cardiovascular events in high-risk atherosclerosis patients with CKD without causing adverse renal events.

Cite This Study

Ridker et al. (2018) conducted an RCT in Chronic Kidney Disease (n=10,061). Canakinumab vs. Placebo was evaluated on Incident myocardial infarction, stroke, hospitalization for unstable angina requiring urgent revascularization, cardiovascular death, or death from any cause. Among 10,061 post-myocardial infarction patients (1,875 with CKD), canakinumab reduced major adverse cardiovascular event rates without adverse clinical renal events.

synapsesocial.com/papers/6a8e06bc5f6d68840b01bc9e https://doi.org/10.1016/j.jacc.2018.03.490

Topics

Women and heart disease

View Full Paper

Ask AI

Bookmark

Implication

Inhibition of IL-1β with canakinumab reduces major adverse cardiovascular events in high-risk atherosclerosis patients with CKD without causing adverse renal events.

Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease

Key Points

Study Design

Structured PICO

Discussion

Implication

Cite This Study

Topics

Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease

Key Points

Study Design

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider